Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes Agents
| Autor: | Justin Northrup, Stephen N. Davis, R. Brodows, David G. Maggs, Hangtao Xu, Don Johns |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Pilot Projects Type 2 diabetes Hypoglycemia Drug Administration Schedule law.invention Randomized controlled trial law Internal medicine Diabetes mellitus Internal Medicine medicine Humans Hypoglycemic Agents Insulin Aged Glycemic Glycated Hemoglobin Advanced and Specialized Nursing Venoms business.industry Blood Glucose Self-Monitoring Middle Aged medicine.disease Glucagon-like peptide-1 Endocrinology Diabetes Mellitus Type 2 Exenatide Drug Therapy Combination Female Peptides business medicine.drug |
| Zdroj: | Diabetes Care. 30:2767-2772 |
| ISSN: | 1935-5548 0149-5992 |
| DOI: | 10.2337/dc06-2532 |
| Popis: | OBJECTIVE— This 16-week study explored the safety of substituting exenatide for insulin in patients with type 2 diabetes using insulin in combination with oral antidiabetes agents. RESEARCH DESIGN AND METHODS— Successful maintenance of glycemic control was predefined as an A1C increase of RESULTS— A total of 62% (18 of 29) of the exenatide-treated patients maintained glycemic control compared with 81% (13 of 16) of the insulin-treated patients. Of the 11 exenatide-treated patients who did not maintain control, 5 discontinued before week 16 because of loss of glucose control. The overall safety profile was generally consistent with previous exenatide trials. The mean overall hypoglycemia rates were 1.72 and 0.97 events/patient-year for the exenatide and insulin reference groups, respectively. CONCLUSIONS— This pilot study suggests that it is feasible to sustain glycemic control when substituting exenatide for insulin. Although it is not possible to characterize clear predictors of outcome given the size and exploratory nature of the study, the data suggest that patients with longer disease duration, who are taking higher doses of insulin and have less endogenous β-cell function, may experience deterioration in glucose control if exenatide is substituted for insulin therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|